Belgian Multidiscplinary Immunotoxicity Board (BITOX)

Overview

Aim: share experiences, standardize approach for irAEs and find clinically relevant research questions

Online questionnaire

approx. 5 minutes to fill in case details
Click here to fill in case details

via smartphone

Please click the following links for a patient information flyer about BITOX in Dutch (NL) and French (FR).

Please note that submitting your case to BITOX does not exempt you from the obligation to submit rare/unexpected AEs to FAMHP.

Questions handled

Diagnosis and management of severe immune related adverse events
Starting immunotherapy in ‘dysimmune’ patients
- transplant patients
- patients with chronic (viral) infections
- patients with autoimmune disorders
- immunosuppressed patients
- rechallenge after irAE
- other
Safety of immunosuppression in a patient with cancer

Bimonthly virtual meeting via Teams

onco/hematologists, organspecialists and interested healthcare professionals
Timing: 1st and 3rd Monday of each month 16:30-17:30
if you are unable to attend, the case can still be discussed with a written recommendation provided

Abbreviations

Abbrevations

IT: Immunotherapy for solid or hematological cancers

irAE: Immune Related Adverse Event

ICI: Immune Checkpoint Inhibition

Dysimmunity: having an characteristic which might influence IT outcome (eg underlying auto immune disease, having previous irAE, chronic viral infection, severe allergy, ….)